{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T10:33:10Z","timestamp":1784802790008,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T00:00:00Z","timestamp":1635552000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T00:00:00Z","timestamp":1635552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Radiol"],"published-print":{"date-parts":[[2022,3]]},"DOI":"10.1007\/s00330-021-08290-1","type":"journal-article","created":{"date-parts":[[2021,10,30]],"date-time":"2021-10-30T04:02:42Z","timestamp":1635566562000},"page":"1663-1675","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Pre-treatment MRI tumor features and post-treatment mammographic findings: may they contribute to refining the prediction of pathologic complete response in post-neoadjuvant breast cancer patients with radiologic complete response on MRI?"],"prefix":"10.1007","volume":"32","author":[{"given":"Bruna M.","family":"Thompson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciano F.","family":"Chala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Shimizu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max S.","family":"Mano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 R.","family":"Filassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe C.","family":"Geyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1911-9090","authenticated-orcid":false,"given":"Ulysses S.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giselle Guedes Netto","family":"de Mello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cl\u00e1udia","family":"da Costa Leite","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,10,30]]},"reference":[{"key":"8290_CR1","doi-asserted-by":"publisher","first-page":"e108405","DOI":"10.1371\/journal.pone.0108405","volume":"9","author":"XS Chen","year":"2014","unstructured":"Chen XS, Yuan Y, Garfield DH, Wu JY, Huang O, Shen KW (2014) Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis. PLoS One 9:e108405","journal-title":"PLoS One"},{"key":"8290_CR2","doi-asserted-by":"publisher","first-page":"2278","DOI":"10.1093\/annonc\/mdt182","volume":"24","author":"A Schneeweiss","year":"2013","unstructured":"Schneeweiss A, Chia S, Hickish T et al (2013) Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol 24:2278\u20132284","journal-title":"Ann Oncol"},{"key":"8290_CR3","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar P, Zhang L, Untch M et al (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384:164\u2013172","journal-title":"Lancet"},{"key":"8290_CR4","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1002\/cncr.27995","volume":"119","author":"JF De Los Santos","year":"2013","unstructured":"De Los Santos JF, Cantor A, Amos KD et al (2013) Magnetic resonance imaging as a predictor of pathologic response in patients treated with neoadjuvant systemic treatment for operable breast cancer. Translational Breast Cancer Research Consortium trial 017. Cancer 119:1776\u20131183","journal-title":"Cancer"},{"issue":"30","key":"8290_CR5","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1200\/JCO.2011.38.8595","volume":"20","author":"G von Minckwitz","year":"2012","unstructured":"von Minckwitz G, Untch M, Blohmer JU et al (2012) Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. J Clin Oncol 20(30):1796\u20131804","journal-title":"J Clin Oncol"},{"key":"8290_CR6","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s13058-018-1091-y","volume":"21","author":"SP Gampenrieder","year":"2019","unstructured":"Gampenrieder SP, Peer A, Weismann C et al (2019) Radiologic complete response (rCR) in contrast-enhanced magnetic resonance imaging (CE-MRI) after neoadjuvant chemotherapy for early breast cancer predicts recurrence-free survival but not pathologic complete response (pCR). Breast Cancer Res 21:19","journal-title":"Breast Cancer Res"},{"key":"8290_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(17)30777-5","volume":"19","author":"Early Breast Cancer Trialists' Collaborative Group (EBCTCG)","year":"2018","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2018) Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials. Lancet Oncol 19:27\u201339","journal-title":"Lancet Oncol"},{"key":"8290_CR8","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1245\/s10434-015-4918-0","volume":"23","author":"B Schaefgen","year":"2016","unstructured":"Schaefgen B, Mati M, Sinn HP et al (2016) Can routine imaging after neoadjuvant chemotherapy in breast cancer predict pathologic complete response? Ann Surg Oncol 23:789\u2013795","journal-title":"Ann Surg Oncol"},{"key":"8290_CR9","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s10549-017-4254-0","volume":"164","author":"MS van Ramshorst","year":"2017","unstructured":"van Ramshorst MS, Loo CE, Groen EJ et al (2017) MRI predicts pathologic complete response in HER2-positive breast cancer after neoadjuvant chemotherapy. Breast Cancer Res Treat 164:99\u2013106","journal-title":"Breast Cancer Res Treat"},{"key":"8290_CR10","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1186\/s12885-015-1664-4","volume":"15","author":"ML Marinovich","year":"2015","unstructured":"Marinovich ML, Macaskill P, Irwig L et al (2015) Agreement between MRI and pathologic breast tumor size after neoadjuvant chemotherapy, and comparison with alternative tests: individual patient data meta-analysis. BMC Cancer 15:662","journal-title":"BMC Cancer"},{"key":"8290_CR11","unstructured":"National Comprehensive Cancer Network. Breast Cancer Version 2.2016"},{"key":"8290_CR12","doi-asserted-by":"publisher","first-page":"e4505","DOI":"10.1136\/bmj.e4505","volume":"345","author":"R Jeevan","year":"2012","unstructured":"Jeevan R, Cromwell DA, Trivella M et al (2012) Reoperation rates after breast conserving surgery for breast cancer among women in England: retrospective study of hospital episode statistics. BMJ 345:e4505","journal-title":"BMJ"},{"key":"8290_CR13","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1016\/j.ejso.2020.08.023","volume":"47","author":"J Woo","year":"2021","unstructured":"Woo J, Ryu JM, Jung SM et al (2021) Breast radiologic complete response is associated with favorable survival outcomes after neoadjuvant chemotherapy in breast cancer. Eur J Surg Oncol 47:232\u2013239","journal-title":"Eur J Surg Oncol"},{"key":"8290_CR14","doi-asserted-by":"publisher","first-page":"1355","DOI":"10.1001\/jamaoncol.2020.2535","volume":"6","author":"D Yee","year":"2020","unstructured":"I-SPY2 Trial Consortium, Yee D, DeMichele AM, Yau C et al (2020) Association of event-free and distant recurrence-free survival with individual-level pathologic complete response in neoadjuvant treatment of stages 2 and 3 breast cancer: three-year follow-up analysis for the I-SPY2 Adaptively Randomized Clinical Trial. JAMA Oncol 6:1355\u20131362","journal-title":"JAMA Oncol"},{"key":"8290_CR15","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1002\/jso.25663","volume":"120","author":"SF Sener","year":"2019","unstructured":"Sener SF, Sargent RE, Lee C et al (2019) MRI does not predict pathologic complete response after neoadjuvant chemotherapy for breast cancer. J Surg Oncol 120:903\u2013910","journal-title":"J Surg Oncol"},{"key":"8290_CR16","doi-asserted-by":"publisher","first-page":"197","DOI":"10.21037\/qims.2019.11.16","volume":"10","author":"X Zhang","year":"2020","unstructured":"Zhang X, Wang D, Liu Z et al (2020) The diagnostic accuracy of magnetic resonance imaging in predicting pathologic complete response after neoadjuvant chemotherapy in patients with different molecular subtypes of breast cancer. Quant Imaging Med Surg 10:197\u2013210","journal-title":"Quant Imaging Med Surg"},{"key":"8290_CR17","doi-asserted-by":"publisher","first-page":"2603","DOI":"10.2147\/CMAR.S247279","volume":"12","author":"K Zhang","year":"2020","unstructured":"Zhang K, Li J, Zhu Q, Chang C (2020) Prediction of pathologic complete response by ultrasonography and magnetic resonance imaging after neoadjuvant chemotherapy in patients with breast cancer. Cancer Manag Res 12:2603\u20132612","journal-title":"Cancer Manag Res"},{"key":"8290_CR18","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1148\/radiol.2018170960","volume":"288","author":"FAK Mazari","year":"2018","unstructured":"Mazari FAK, Sharma N, Dodwell D, Horgan K (2018) Human epidermal growth factor 2-positive breast cancer with mammographic microcalcification: relationship to pathologic complete response after neoadjuvant chemotherapy. Radiology 288:366\u2013374","journal-title":"Radiology"},{"key":"8290_CR19","doi-asserted-by":"publisher","first-page":"1492","DOI":"10.1245\/s10434-016-5741-y","volume":"24","author":"Y Feliciano","year":"2017","unstructured":"Feliciano Y, Mamtani A, Morrow M, Stempel MM, Patil S, Jochelson MS (2017) Do calcifications seen on mammography after neoadjuvant chemotherapy for breast cancer always need to be excised? Ann Surg Oncol 24:1492\u20131498","journal-title":"Ann Surg Oncol"},{"key":"8290_CR20","unstructured":"B.I.R.A.D.S. American College of Radiology (ACR). ACR Breast Imaging Reporting and Data System (BI-RADS, 5th edn. American College of Radiology, Reston"},{"key":"8290_CR21","volume-title":"Manual de condutas em oncologia","author":"PMG Hoff","year":"2019","unstructured":"Hoff PMG, Diz MDPE, Testa L (2019) Manual de condutas em oncologia , 3rd edn. Atheneu, Rio de Janeiro","edition":"3rd"},{"key":"8290_CR22","unstructured":"Ribeiro J\u00fanior U, Kulcsar MAV. Manual de condutas em oncologia cir\u00fargica. Autor, S\u00e3o Paulo"},{"key":"8290_CR23","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/modpathol.2015.53","volume":"28","author":"F Peintinger","year":"2015","unstructured":"Peintinger F, Sinn B, Hatzis C et al (2015) Reproducibility of residual cancer burden for prognostic assessment of breast cancer after neoadjuvant chemotherapy. Mod Pathol 28:913\u2013920","journal-title":"Mod Pathol"},{"key":"8290_CR24","unstructured":"Kirkwood BR, Sterne JAC. Essential medical Statistics, 2nd edn. Blackwell Science, Massachusetts"},{"key":"8290_CR25","unstructured":"Hosmer DW, Lemeshow S, Sturdivant RX. Applied logistic regression, 3nd edn. Wiley, New York"},{"key":"8290_CR26","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1148\/radiol.2018181846","volume":"289","author":"NM Hylton","year":"2018","unstructured":"Hylton NM (2018) Residual disease after neoadjuvant therapy for breast cancer: can MRI Help? Radiology 289:335\u2013336","journal-title":"Radiology"},{"key":"8290_CR27","doi-asserted-by":"publisher","first-page":"3149","DOI":"10.1245\/s10434-011-1912-z","volume":"18","author":"KP McGuire","year":"2011","unstructured":"McGuire KP, Toro-Burguete J, Dang H et al (2011) MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy? Ann Surg Oncol 18:3149\u20133154","journal-title":"Ann Surg Oncol"},{"key":"8290_CR28","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.2214\/ajr.179.5.1791193","volume":"179","author":"SC Partridge","year":"2002","unstructured":"Partridge SC, Gibbs JE, Lu Y, Esserman LJ, Sudilovsky D, Hylton NM (2002) Accuracy of MR imaging for revealing residual breast cancer in patients who have undergone neoadjuvant chemotherapy. AJR Am J Roentgenol 179:1193\u20131199","journal-title":"AJR Am J Roentgenol"},{"key":"8290_CR29","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s13244-013-0219-y","volume":"4","author":"MB Lobbes","year":"2013","unstructured":"Lobbes MB, Prevos R, Smidt M et al (2013) The role of magnetic resonance imaging in assessing residual disease and pathologic complete response in breast cancer patients receiving neoadjuvant chemotherapy: a systematic review. Insights Imaging 4:163\u2013175","journal-title":"Insights Imaging"},{"key":"8290_CR30","doi-asserted-by":"publisher","first-page":"3823","DOI":"10.1245\/s10434-013-3038-y","volume":"20","author":"RA Mukhtar","year":"2013","unstructured":"Mukhtar RA, Yau C, Rosen M, Tandon VJ, I-SPY 1 TRIAL and ACRIN 6657 Investigators, Hylton N, Esserman LJ (2013) Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007\/150012; ACRIN 6657). Ann Surg Oncol 20:3823\u20133830","journal-title":"Ann Surg Oncol"},{"key":"8290_CR31","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1016\/j.ejrad.2019.06.017","volume":"118","author":"WJ Choi","year":"2019","unstructured":"Choi WJ, Kim HH, Cha JH, Shin HJ, Chae EY, Yoon GY (2019) Complete response on MR imaging after neoadjuvant chemotherapy in breast cancer patients: factors of radiologic-pathologic discordance. Eur J Radiol 118:114\u2013121","journal-title":"Eur J Radiol"},{"key":"8290_CR32","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1245\/s10434-015-4403-9","volume":"22","author":"V Dialani","year":"2015","unstructured":"Dialani V, Chadashvili T, Slanetz PJ (2015) Role of imaging in neoadjuvant therapy for breast cancer. Ann Surg Oncol 22:1416\u20131424","journal-title":"Ann Surg Oncol"},{"key":"8290_CR33","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1148\/radiol.11110814","volume":"261","author":"JH Chen","year":"2011","unstructured":"Chen JH, Bahri S, Mehta RS et al (2011) Breast cancer: evaluation of response to neoadjuvant chemotherapy with 3.0-T MR imaging. Radiology 261:735\u2013743","journal-title":"Radiology"},{"key":"8290_CR34","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1093\/jnci\/djs528","volume":"105","author":"ML Marinovich","year":"2013","unstructured":"Marinovich ML, Houssami N, Macaskill P et al (2013) Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. J Natl Cancer 105:321\u2013333","journal-title":"J Natl Cancer"},{"key":"8290_CR35","doi-asserted-by":"publisher","first-page":"3310","DOI":"10.1245\/s10434-014-3914-0","volume":"21","author":"A Weiss","year":"2014","unstructured":"Weiss A, Lee KC, Romero Y et al (2014) Calcifications on mammogram do not correlate with tumor size after neoadjuvant chemotherapy. Ann Surg Oncol 21:3310\u20133316","journal-title":"Ann Surg Oncol"},{"key":"8290_CR36","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1245\/s10434-015-4993-2","volume":"23","author":"YS Kim","year":"2016","unstructured":"Kim YS, Chang JM, Moon HG, Lee J, Shin SU, Moon WK (2016) Residual mammographic microcalcifications and enhancing lesions on MRI after neoadjuvant systemic chemotherapy for locally advanced breast cancer: correlation with histopathologic residual tumor size. Ann Surg Oncol 23:1135\u20131142","journal-title":"Ann Surg Oncol"},{"key":"8290_CR37","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1177\/0284185118776491","volume":"60","author":"H Yim","year":"2019","unstructured":"Yim H, Ha T, Kang DK, Park SY, Jung Y, Kim TH (2019) Change in microcalcifications on mammography after neoadjuvant chemotherapy in breast cancer patients: correlation with tumor response grade and comparison with lesion extent. Acta Radiol 60:131\u2013139","journal-title":"Acta Radiol"},{"key":"8290_CR38","doi-asserted-by":"publisher","first-page":"20180123","DOI":"10.1259\/bjr.20180123","volume":"91","author":"SA Henderson","year":"2018","unstructured":"Henderson SA, Muhammad Gowdh N, Purdie CA et al (2018) Breast cancer: influence of tumour volume estimation method at MRI on prediction of pathological response to neoadjuvant chemotherapy. Br J Radiol 91:20180123","journal-title":"Br J Radiol"},{"key":"8290_CR39","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1148\/radiol.2015150013","volume":"279","author":"NM Hylton","year":"2016","unstructured":"Hylton NM, Gatsonis CA, Rosen MA et al (2016) Neoadjuvant chemotherapy for breast cancer: functional tumor volume by MR imaging predicts recurrence-free survival-results from the ACRIN 6657\/CALGB 150007 I-SPY 1 TRIAL. Radiology 279:44\u201355","journal-title":"Radiology"}],"container-title":["European Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-021-08290-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00330-021-08290-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00330-021-08290-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,11]],"date-time":"2022-02-11T04:44:23Z","timestamp":1644554663000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00330-021-08290-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,30]]},"references-count":39,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2022,3]]}},"alternative-id":["8290"],"URL":"https:\/\/doi.org\/10.1007\/s00330-021-08290-1","relation":{},"ISSN":["0938-7994","1432-1084"],"issn-type":[{"value":"0938-7994","type":"print"},{"value":"1432-1084","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,10,30]]},"assertion":[{"value":"5 June 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 October 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The scientific guarantor of this publication is Bruna Thompson.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Guarantor"}},{"value":"The authors of this manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"No complex statistical methods were necessary for this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Statistics and biometry"}},{"value":"Written informed consent was waived by the Institutional Review Board.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Institutional Review Board approval was obtained.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"\u2022 retrospective\u2022 observational\u2022 performed at one institution","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Methodology"}}]}}